Health policy in America has shifted rapidly over the last decade, and states are increasingly exercising greater authority over health policy decision-making. This localization and regionalization of healthcare policy poses significant challenges for patients with cancer, providers, advocates, and policymakers. To identify the challenges and opportunities that lay ahead of stakeholders, NCCN hosted the 2019 Policy Summit: The State of Cancer Care in America on June 27, 2019, in Washington, DC. The summit featured multidisciplinary panel discussions to explore the implications for access to quality cancer care within a shifting health policy landscape from a patient, provider, and lawmaker perspective. This article encapsulates the discussion from this NCCN Policy Summit.
Demographic factors such as race, socioeconomic status, gender identity, area of residence, native language, and cultural barriers have an effect on outcomes in cancer care. To identify unmet needs, challenges, and opportunities in achieving high-quality, patient-centered cancer care for all, NCCN conducted a yearlong environmental scan, which involved stakeholder meetings with patients and patient advocacy groups to discuss these topics. The findings from this scan informed the corresponding NCCN Patient Advocacy Summit: Advocating for Equity in Cancer Care, held in Washington, DC, on December 10, 2018. In addition to the many patient advocacy groups, the summit featured a number of other stakeholders that advocate for equity in cancer care. This article encapsulates the findings of the environmental scan and the discussion from the NCCN Patient Advocacy Summit.
educational and training (ETE) intervention is the first intervention to address the need among patients and the first to provide a hands-on experience with potential MIBC treatment options to enhance patient health care and adjustment following treatment.METHODS: Eligible MIBC patients (N ¼ 25) were recruited from Mount Sinai Hospital between 2014-and 2016 and were randomized into control or intervention groups. All patients were consented and completed a baseline questionnaire. Intervention group then received an educational session about MIBC treatments and were provided with detailed BC treatment information. Patients from both groups were asked to complete an additional questionnaire at 1 month after treatment.RESULTS: Patients in intervention group (n ¼ 17) showed significant improvement in MIBC knowledge (baseline vs. 1 month: 35AE6.6 vs. 29AE5.0, p<0.01) but not in the control group (n¼ 8). Most of the MIBC patients (84%) in the intervention group agreed that the intervention increased their knowledge about bladder cancer and its treatment and, importantly, 64% of the patients claimed that the intervention helped them make treatment decision. Most patients (73%) also agreed that the intervention helped them talk to their doctors about their treatment and made them feel less anxious or upset. Ninety-one percent of the patients in the intervention group stated that they would recommend the educational materials to other MIBC patients CONCLUSIONS: This pilot study suggested that the ETE intervention provide MIBC patients with useful treatment information and give them confidence in treatment decision making. It is worth to further investigate the application of ETE intervention in BC patients on the health-related quality of life after treatment.
As the oncology ecosystem shifts from service-based care to outcomes and value-based care, stakeholders cite concerns regarding the lack of patient experience data that are important to the patient community. To address the patient perspective and highlight the challenges and opportunities within policy and clinical decision-making to improve patient-centered care, NCCN hosted the NCCN Patient Advocacy Summit: Delivering Value for Patients Across the Oncology Ecosystem on December 11, 2019, in Washington, DC. The summit featured multidisciplinary panel discussions, keynote speakers, and patient advocate presentations exploring the implications for patient-centered care within a shifting health policy landscape. This article encapsulates and expounds upon the discussions and presentations from the summit.
The cost of delivering high-quality healthcare in America now consumes 17.7% of the nation’s gross domestic product according to Centers for Medicare & Medicaid Services National Health Expenditure Data. With costs threatening to disrupt accessible and equitable care for patients, policymakers are reassessing all matters and functions of the healthcare system to excise waste, redundancies, and costly services. To explore this subjects’ impact on oncology, NCCN hosted the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care. This virtual summit featured multidisciplinary panel discussions and keynote addresses. Seeking to address barriers to low-cost, high-quality cancer care, panelists and keynotes presented innovative policy solutions to sustain high-quality oncologic care at lower costs to the health system. This article encapsulates the discussions held during the summit and expounds upon salient points where appropriate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.